ClinicalTrials.gg
RecruitingNCT07709780APEXUpdated Jul 17, 2026

Apixaban Versus Warfarin for Left Ventricular Thrombus

A Phase 3 interventional study of Apixaban and Warfarin in Left Ventricular Thrombus, sponsored by University of Arizona. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by University of Arizona · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing apixaban in Stroke — 5 open to participants now, 5 under way, 3 of them phase 3. apixaban · Stroke.

Planned enrollment
8th of 11
218 · median 840
Started
2026
with 1 other
Phase 3
5 of 11
3 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
University of Arizona

Among the 11 studies testing apixaban in Stroke, this one is the 8th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 3, and was the 11th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

5 of the 11 studies testing apixaban in Stroke are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing apixaban in Stroke, or all of them as a file.
02

Study summary

Left ventricular thrombus is a blood clot that forms in the left ventricle and is associated with risk of systemic embolism and ischemic stroke. Warfarin has historically been used for anticoagulation in this condition, but it requires frequent international normalized ratio monitoring and is affected by dietary and drug interactions. Apixaban is a direct oral factor Xa inhibitor with fixed dosing and no routine anticoagulation monitoring requirement, and it is increasingly used in clinical practice for left ventricular thrombus, although definitive randomized evidence remains limited.

This randomized, noninferiority trial will compare apixaban with warfarin for treatment of left ventricular thrombus. Eligible adults with recently confirmed left ventricular thrombus will be randomized 1:1 to apixaban or warfarin. The primary endpoint is complete left ventricular thrombus resolution at 3 months assessed by cardiac magnetic resonance imaging. Participants will be followed through 12 months for thrombus-related, bleeding, cardiovascular, and mortality outcomes.

03

Conditions studied

  • Left Ventricular Thrombus

Browse trials for

Keywords

  • Cardiac Thrombus
  • Intracardiac Thrombus
  • Systemic Embolism
  • Stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • LV thrombus confirmed within 14 days prior to randomization by CMR or contrast TTE or cardiac CT; baseline CMR required pre-randomization (or ≤7 days post-randomization if clinically unavoidable)
  • Candidate for oral anticoagulation for ≥3 months
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • Absolute indication for VKA (mechanical valve, moderate-severe rheumatic MS and antiphospholipid syndrome) or clear preference or for one of the study drugs precluding randomization (see below)
  • Antiphospholipid syndrome
  • Estimated \<15 mL/min or dialysis
  • Severe hepatic impairment (ICD-10: K70.40, K70.41, K71.10, K71.11, K72.00, K72.01, K72.10, K72.11, K72.90, K72.91)
  • Active bleeding
  • \<50,000/µL
  • Pregnancy or lactation; women of unwilling to use
  • \<1 year or other conditions compromising follow-up

Additional contraindications to use of warfarin or apixaban. This includes, but is not limited to:

  • Active pathological bleeding, major bleeding diathesis, or known blood dyscrasia
  • Recent or planned surgery involving the central nervous system or eye, traumatic surgery with large open surfaces, or procedures (spinal/epidural puncture or major regional block anesthesia) where bleeding cannot be safely controlled.
  • Conditions associated with high risk of bleeding such as threatened abortion, eclampsia, severe preeclampsia, or malignant/uncontrolled hypertension.
  • History of severe or allergy to warfarin or apixaban.
  • Ongoing treatment with a combined P-gp and strong inhibitor or inducer that cannot be safely discontinued or substituted. Examples include strong combined inhibitors such as ketoconazole, itraconazole, ritonavir or posiconazole, and strong combined inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
218 participants (estimated)

Study arms

  • Experimental
    Apixaban

    Participants randomized to apixaban will receive oral apixaban for treatment of left ventricular thrombus according to standard clinical dosing and follow-up.

    Drug: Apixaban

  • Active comparator
    Warfarin

    Participants randomized to warfarin will receive oral dose-adjusted warfarin for treatment of left ventricular thrombus according to standard clinical care.

    Drug: Warfarin

Interventions

  • Apixaban 5 mg orally twice daily

  • Warfarin will be prescribed with dose adjustment to maintain INR 2.0-3.0.

06

What researchers measure

Primary outcomes

  1. Complete Left Ventricular Thrombus Resolution at 3 Months

    Proportion of participants with complete resolution of left ventricular thrombus at 3 months, assessed by cardiac magnetic resonance imaging. The primary noninferiority comparison will use the absolute between-group difference in the proportion of participants with complete thrombus resolution, apixaban minus warfarin.

    Time frame: 3 months after randomization

Secondary outcomes

  1. Major Bleeding

    Proportion of participants with major bleeding defined as BARC type 3 or 5 bleeding.

    Time frame: 6 months

  2. Change in LV Thrombus Volume

    Change in thrombus volume assessed by CMR

    Time frame: Baseline to 3, 6, or 12 months

  3. Left Ventricular Remodeling

    Change in left ventricular ejection fraction and left ventricular volumes on follow-up imaging.

    Time frame: Baseline to 3, 6,12 months

  4. Recurrent LV Thrombus

    Proportion of participants with recurrent LV thrombus after documented resolution.

    Time frame: 12 months

  5. Ischemic Stroke

    Proportion of participants with ischemic stroke.

    Time frame: 12 months

  6. Systemic embolism

    Proportion of participants with systemic embolism

    Time frame: 12 months

  7. Cardiovascular Mortality

    Proportion of participants with cardiovascular death.

    Time frame: 12 months

  8. All-Cause Mortality

    Proportion of participants with death from any cause.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Banner University Medical Center - Tucson
    Tucson, Arizona 85724, United States
    Recruiting
    • Tushar Acharya, MD, MPH · Principal investigator
    • Song Peng Ang, MD · Principal investigator
    • Alane Blythe C Dy, PhD, MSPH · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jul 2028, 24 months later.

Of 93 non-industry phase 3 interventional studies under Stroke, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 24 months is below that.

Counting every sponsor, half of 130 studies reached it within 44 months; a quarter within 27 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 17, 2026
StartEst.
Jun 22, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2029
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07709780
Responsible party
Tushar Acharya (Associate Professor, University of Arizona) — Principal investigator
First posted
Jul 17, 2026
Start date
Jun 22, 2026 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Jul 17, 2026

Study contacts

Tushar Acharya, MD, MPH
Contact
tacharya@arizona.edu
520-626-0968

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion